英国公司在治疗癌症等疾病中的肌肉消瘦新药方面获得了美国和欧盟的专利权。 UK firm Actimed gains US and EU patents for a new drug to treat muscle wasting in diseases like cancer.

美国和欧洲专利局对S-pindolol Benzoate(ACM-0011)颁发了新的专利(ACM-001),该化合物旨在治疗癌症缓冲症等条件下的肌肉消瘦。 UK-based Actimed Therapeutics has received new patents from the US and European patent offices for S-pindolol benzoate (ACM-001.1), a compound aimed at treating muscle wasting in conditions like cancer cachexia. 这些专利加强了该公司的知识产权,并支持进一步临床开发ACM-001.1用于治疗肌肉消瘦障碍。 These patents strengthen the company's intellectual property and support further clinical development of ACM-001.1 for treating muscle wasting disorders.